
Releases
Neurizon Accelerates ALS Drug Trial Results to Mid-2027
Neurizon Therapeutics has completed participant recruitment for the NUZ-001 regimen of the HEALEY ALS Platform Trial in under five months. This record-breaking enrollment pace has allowed the company to pull forward its anticipated topline efficacy and safety data readout to late Q2 2027.























